[go: up one dir, main page]

MX2023012483A - Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. - Google Patents

Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.

Info

Publication number
MX2023012483A
MX2023012483A MX2023012483A MX2023012483A MX2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A MX 2023012483 A MX2023012483 A MX 2023012483A
Authority
MX
Mexico
Prior art keywords
treatment
chronic pain
pharmaceutical formulations
transdermal pharmaceutical
transdermal
Prior art date
Application number
MX2023012483A
Other languages
English (en)
Inventor
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2023012483A publication Critical patent/MX2023012483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente revelación se refiere a la administración transdérmica de agentes activos, tales como diclofenaco y/o CBD y/o THC, y derivados de estos compuestos, para el tratamiento y/o prevención y/o control del dolor crónico.
MX2023012483A 2021-04-22 2022-04-21 Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico. MX2023012483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163177981P 2021-04-22 2021-04-22
PCT/IB2022/053730 WO2022224184A1 (en) 2021-04-22 2022-04-21 Transdermal pharmaceutical formulations for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
MX2023012483A true MX2023012483A (es) 2023-11-03

Family

ID=83722736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012483A MX2023012483A (es) 2021-04-22 2022-04-21 Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.

Country Status (8)

Country Link
US (1) US20220347151A1 (es)
EP (1) EP4326252A4 (es)
JP (1) JP2024514362A (es)
CN (1) CN117545478A (es)
AU (1) AU2022260813A1 (es)
CA (1) CA3215685A1 (es)
MX (1) MX2023012483A (es)
WO (1) WO2022224184A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CN119896633A (zh) * 2025-01-17 2025-04-29 中国人民解放军空军军医大学 一种水凝胶冷敷贴及其制备的冷热敷贴套装和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990026792A (ko) * 1997-09-26 1999-04-15 김윤 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제
MX2011011514A (es) * 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3355874A4 (en) * 2015-09-30 2019-06-12 George Edward Hoag TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF
WO2018090022A2 (en) * 2016-11-14 2018-05-17 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
EP3737360A1 (en) * 2018-01-12 2020-11-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
CA3060926A1 (en) * 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
US20200197359A1 (en) * 2018-09-17 2020-06-25 Cody D. Freeze Cannabinoid and Terpene-Infused Topical Cream
JP2022524780A (ja) * 2019-03-12 2022-05-10 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
CA3144250A1 (en) * 2019-06-28 2020-12-30 Nexzol Pharma, Inc. Transdermal formulations
JP2022550569A (ja) * 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
CA3155176A1 (en) * 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) * 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) * 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2022004258A (es) * 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
EP4196114A4 (en) * 2020-08-17 2024-10-30 Pike Therapeutics, Inc. TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂

Also Published As

Publication number Publication date
EP4326252A4 (en) 2025-03-12
US20220347151A1 (en) 2022-11-03
WO2022224184A1 (en) 2022-10-27
EP4326252A1 (en) 2024-02-28
CA3215685A1 (en) 2022-10-27
JP2024514362A (ja) 2024-04-01
AU2022260813A1 (en) 2023-10-26
CN117545478A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
MX2023000314A (es) Formulaciones farmaceuticas transdermicas de cannabinoides.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
PH12020550341A1 (en) Niraparib formulations
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
WO2014160216A3 (en) Dual targeting anticancer agents
ZA202000028B (en) Use of vibegron to treat overactive bladder
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2023012483A (es) Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2022012033A (es) Agente terapeutico para infeccion por coronavirus.
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна